Publications

Cerchietti LCA, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BMC.  2005.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.. J Neurooncol. 71(1):73-81.

Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.

Cerchietti L.  2007.  Morphine mouthwashes for painful mucositis.. Support Care Cancer. 15(1):115-6;authorreply117.

Cerchietti L, Leonard JP.  2013.  Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.. Hematology Am Soc Hematol Educ Program. 2013:591-5.

Cerchietti LCA, Navigante AH, Bonomi MR, Zaderajko MA, Menéndez PR, Pogany CE, Roth BMC.  2002.  Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.. Cancer. 95(10):2230-6.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.

Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH et al..  2010.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.. Cancer Cell. 17(4):400-11.

Cerchietti LCA, Navigante AH, Körte MW, Cohen AM, Quiroga PN, Villaamil EC, Bonomi MR, Roth BM.  2003.  Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study.. Pain. 105(1-2):265-73.

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.

Cerchietti LC, Yang SNing, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.  2009.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.. Blood. 113(15):3397-405.

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SNing, Ye K, Farinha P, Horsman DE, Gascoyne RD et al..  2009.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.. Blood. 113(22):5536-48.

Clauzure M, Delgado MATáquez, Phillip JM, Revuelta MV, Cerchietti L, Medina VA.  2022.  Histamine H4 Receptor Agonism Induces Antitumor Effects in Human T-Cell Lymphoma.. Int J Mol Sci. 23(3)

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM et al..  2013.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.. PLoS Genet. 9(1):e1003137.

Deb D, Rajaram S, Larsen JE, Dospoy PP, Marullo R, Li L-S, Avila K, Cerchietti L, Xue F, Minna J et al..  2017.  Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers.. Cancer Res.

Diament MJudith, Peluffo GDaniel, Stillitani I, Cerchietti LCarlos, Navigante A, Ranuncolo SMaris, Klein SMariana.  2006.  Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.. Cancer Invest. 24(2):126-31.

Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick AM, Elemento O.  2017.  Effective combination therapies for B cell lymphoma predicted by a virtual disease model.. Cancer Res.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Dupont T, Yang SNing, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.  2016.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.. Oncotarget. 7(3):3520-32.

Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon S-mi, Nahar R, Braig M et al..  2011.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.. Nature. 473(7347):384-8.

Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.

Fernando TM, Marullo R, Gresely BPera, Phillip JM, Yang SNing, Lundell-Smith G, Torregroza I, Ahn H, Evans T, Gyorffy B et al..  2019.  BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress.. Cancer Discov.

Fiore D, Cappelli LVincenzo, Zumbo P, Phillips JM, Liu Z, Cheng S, Yoffe L, Ghione P, Di Maggio F, Dogan A et al..  2020.  A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries.. Cancers (Basel). 12(6)